MatthewRettigMD

Oncology • Los Angeles, CA

Associate Professor, Medicine, UCLA School of Medicine

Join to view full profile

Dr. Rettig is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Rettig's full profile

Already have an account?

Office
200 UCLA Medical Plz
Ste 140
Los Angeles, CA 90095
Phone+1 310-794-7152

Fax+1 310-794-1666

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 1993 - 1996
University of WashingtonResidency, Internal Medicine, 1991 - 1993
University of Southern California/Los Angeles General Medical Center (USC/LA General)Internship, Internal Medicine, 1990 - 1991
Duke University School of MedicineClass of 1990

Certifications & Licensure

CA State Medical License 1993 - 2027
American Board of Internal Medicine Medical Oncology

Clinical Trials

A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer Start of enrollment: 2012 Dec 01
Terminated
Phase 2
Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC
No longer available
Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer Start of enrollment: 2014 Sep 23
Active, not recruiting
Phase 2
Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide Start of enrollment: 2013 Mar 12
Completed
Compassionate Use: Progressive Metastatic Castrate Resistant Prostate Cancer; Monotherapy Treatment With Trametinib
No longer available
Carboplatin or Olaparib for BRcA Deficient Prostate Cancer Start of enrollment: 2019 Oct 01
Recruiting
Phase 2
Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization Start of enrollment: 2020 Jul 06
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

Low- and High-Volume Disease in Metastatic Hormone-Sensitive Prostate Cancer: From CHAARTED to PSMA PET-An International Multicenter Retrospective Study.
Lena M Unterrainer, Thomas A Hope, Wolfgang P Fendler, Tristan Grogan, Honest Ndlovu
Journal of Nuclear Medicine. 2025-01-03
PSMA-PET/CT Findings in Patients With High-Risk Biochemically Recurrent Prostate Cancer With No Metastatic Disease by Conventional Imaging.
Adrien Holzgreve, Wesley R Armstrong, Kevyn J Clark, Matthias R Benz, Clayton P Smith
JAMA Network Open. 2025-01-02
1 citations
Testosterone Recovery Following Androgen Suppression and Prostate Radiotherapy (TRANSPORT): A Pooled Analysis of Five Randomized Trials from the Meta-Analysis of Rando...
Wee Loon Ong, Tahmineh Romero, Soumyajit Roy, John Nikitas, David Joseph
European Urology. 2025-01-01

Journal Articles

Functional Profiling of Circulating Tumor Cells with an Integrated Vortex Capture and Single-Cell Protease Activity Assay
Steven M Dubinett, Matthew B Rettig, Proceedings of the National Academy of Sciences

Press Mentions

INmune Bio Advances Prostate Cancer Trial at VA HospitalJanuary 28th, 2025
INmune Bio Inc. Expands INKmune Trial in Prostate Cancer to VeteransJanuary 28th, 2025
INmune Bio Inc. Expands INKmune Trial in Prostate Cancer to VeteransJanuary 28th, 2025
Join now to see all